We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Neurology

Journal Scan / Research · July 14, 2021

Efgartigimod Shows Efficacy and Safety in Generalised Myasthenia Gravis

The Lancet Neurology


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Neurology
Safety, Efficacy, and Tolerability of Efgartigimod in Patients With Generalised Myasthenia Gravis (ADAPT): A Multicentre, Randomised, Placebo-Controlled, Phase 3 Trial
Lancet Neurol 2021 Jul 01;20(7)526-536, JF Howard, V Bril, T Vu, C Karam, S Peric, T Margania, H Murai, M Bilinska, R Shakarishvili, M Smilowski, A Guglietta, P Ulrichts, T Vangeneugden, K Utsugisawa, J Verschuuren, R Mantegazza

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading